Biologics Define New Standard of Therapy in Psoriasis
Summary
Barcelona, Spain, September 08, 2006 --( The four anti-TNF biologics already approved or in late stage clinical development achieved a 75 % reduction of the psoriasis area and severity index (PASI) in about 70 % of patients.The most recent introduction of the combination product of calcipotriene and beclomethasone as a once-daily gel or ointment from LEO Pharma and Warner Chilcott has the potential to challenge the biologicals as it also achieves a high level efficacy at a cost of only about EURO 100 per year.The findings of the search can be acquired at www.pipelinereview.com, La Merie’s News Center and Online Store.The four anti-TNF biologics already approved or in late stage clinical development achieved a 75 % reduction of the psoriasis area and severity index (PASI) in about 70 % of patients.Despite annual treatment costs of about US$ 10,000 to 20,000, the British NICE issued guidance for the use of targeted biological therapies to treat adult patients with severe plaque psoriasis.The most recent introduction of the combination product of calcipotriene and beclomethasone as a once-daily gel or ointment from LEO Pharma and Warner Chilcott has the potential to challenge the biologicals as it also achieves a high level efficacy at a cost of only about EURO 100 per year.